References Cited in Appendix D (in Alphabetical Order)

1. Bazso A, Consolaro A, Ruperto N, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol. 2009;36(1):183–90. [PubMed: 19208532]
2. Bekkering WP, ten Cate R, van Rossum MA, et al. A comparison of the measurement properties of the Juvenile Arthritis Functional Assessment Scale with the childhood health assessment questionnaire in daily practice. Clin Rheumatol. 2007;26(11):1903–7. [PMC free article: PMC2039777] [PubMed: 17700993]
3. Bekkering WP, ten Cate R, van Suijlekom-Smit LW, et al. The relationship between impairments in joint function and disabilities in independent function in children with systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28(5):1099–105. [PubMed: 11361196]
4. Brewer EJ, Giannini EH, Kuzmina N, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986;314(20):1269–76. [PubMed: 3517643]
5. Brown GT, Wright FV, Lang BA, et al. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis Rheum. 2005;53(6):897–904. [PubMed: 16342103]
6. Brunner HI, Johnson AL, Barron AC, et al. Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire. J Clin Rheumatol. 2005;11(4):194–204. [PubMed: 16357756]
7. Brunner HI, Klein-Gitelman MS, Miller MJ, et al. Minimal clinically important differences of the childhood health assessment questionnaire. J Rheumatol. 2005;32(1):150–61. [PubMed: 15630741]
8. Brunner HI, Klein-Gitelman MS, Miller MJ, et al. Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. Arthritis Rheum. 2004;51(5):763–73. [PubMed: 15478144]
9. Brunner HI, Lovell DJ, Finck BK, et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002;29(5):1058–64. [PubMed: 12022323]
10. Cespedes-Cruz A, Gutierrez-Suarez R, Pistorio A, et al. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67(3):309–14. [PubMed: 17875547]
11. Consolaro A, Vitale R, Pistorio A, et al. Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. J Rheumatol. 2007;34(8):1773–6. [PubMed: 17611978]
12. Dempster H, Porepa M, Young N, et al. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum. 2001;44(8):1768–74. [PubMed: 11508427]
13. Filocamo G, Davi S, Pistorio A, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37(7):1534–41. [PubMed: 20551105]
14. Filocamo G, Sztajnbok F, Cespedes-Cruz A, et al. Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(6):913–20. [PubMed: 17665481]
15. Geerdink LM, Prince FH, Looman CW, et al. Development of a digital Childhood Health Assessment Questionnaire for systematic monitoring of disease activity in daily practice. Rheumatology (Oxford). 2009;48(8):958–63. [PubMed: 19509189]
16. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326(16):1043–9. [PubMed: 1549149]
17. Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1996;23(5):919–24. [PubMed: 8724309]
18. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202–9. [PubMed: 9214419]
19. Hoza J, Kadlecova T, Nemcova D, et al. Sulphasalazine and Delagil--a comparative study in patients with juvenile chronic arthritis. Acta Univ Carol Med (Praha). 1991;37(1-2):80–3. [PubMed: 1688268]
20. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129–37. [PubMed: 18766426]
21. Kvien TK, Hoyeraal HM, Sandstad B. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis--evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol. 1985;12(3):533–9. [PubMed: 3930720]
22. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986;13(1):118–23. [PubMed: 3517321]
23. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62(3):245–7. [PMC free article: PMC1754468] [PubMed: 12594111]
24. Len C, Goldenberg J, Ferraz MB, et al. Crosscultural reliability of the Childhood Health Assessment Questionnaire. J Rheumatol. 1994;21(12):2349–52. [PubMed: 7699641]
25. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763–9. [PubMed: 10717011]
26. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003;48(1):218–26. [PubMed: 12528122]
27. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20. [PubMed: 18716298]
28. Lurati A, Pontikaki I, Teruzzi B, et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2006;54(5):1602–7. [PubMed: 16646003]
29. Magni-Manzoni S, Cugno C, Pistorio A, et al. Responsiveness of clinical measures to flare of disease activity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2005;23(3):421–5. [PubMed: 15971436]
30. Moretti C, Viola S, Pistorio A, et al. Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. Ann Rheum Dis. 2005;64(2):257–61. [PMC free article: PMC1755364] [PubMed: 15647433]
31. Oliveira S, Ravelli A, Pistorio A, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007;57(1):35–43. [PubMed: 17266064]
32. Oppermann J, Mobius D. Therapeutical and immunological effects of methylprednisolone pulse therapy in comparison with intravenous immunoglobulin. Treatment in patients with juvenile chronic arthritis. Acta Univ Carol Med (Praha). 1994;40(1-4):117–21. [PubMed: 9355686]
33. Palmisani E, Solari N, Magni-Manzoni S, et al. Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis Rheum. 2006;55(6):843–9. [PubMed: 17139659]
34. Pouchot J, Ecosse E, Coste J, et al. Validity of the childhood health assessment questionnaire is independent of age in juvenile idiopathic arthritis. Arthritis Rheum. 2004;51(4):519–26. [PubMed: 15334422]
35. Pouchot J, Larbre JP, Lemelle I, et al. Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis. Joint Bone Spine. 2002;69(5):468–81. [PubMed: 12477231]
36. Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind, multicenter study. Arthritis Rheum. 1985;28(4):376–82. [PubMed: 3885958]
37. Riddle R, Ryser CN, Morton AA, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006;31(3):262–71. [PubMed: 15872147]
38. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91. [PubMed: 18632147]
39. Ruperto N, Ravelli A, Falcini F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis. 1998;57(1):38–41. [PMC free article: PMC1752459] [PubMed: 9536821]
40. Ruperto N, Ravelli A, Migliavacca D, et al. Responsiveness of clinical measures in children with oligoarticular juvenile chronic arthritis. J Rheumatol. 1999;26(8):1827–30. [PubMed: 10451084]
41. Saad-Magalhaes C, Pistorio A, Ravelli A, et al. Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index? Ann Rheum Dis. 2010;69(1):82–7. [PubMed: 19221399]
42. Sawyer MG, Carbone JA, Whitham JN, et al. The relationship between health-related quality of life, pain, and coping strategies in juvenile arthritis--a one year prospective study. Qual Life Res. 2005;14(6):1585–98. [PubMed: 16110938]
43. Selvaag AM, Flato B, Lien G, et al. Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. J Rheumatol. 2003;30(7):1602–10. [PubMed: 12858465]
44. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352(16):1655–66. [PubMed: 15843668]
45. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994;21(12):2353–8. [PubMed: 7699642]
46. Singh G, Athreya BH, Fries JF, et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761–9. [PubMed: 7986222]
47. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23. [PubMed: 15696578]
48. Stephens S, Singh-Grewal D, Bar-Or O, et al. Reliability of exercise testing and functional activity questionnaires in children with juvenile arthritis. Arthritis Rheum. 2007;57(8):1446–52. [PubMed: 18050186]
49. Sztajnbok F, Coronel-Martinez DL, Diaz-Maldonado A, et al. Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. Rheumatology (Oxford). 2007;46(1):141–5. [PubMed: 16782733]
50. Takken T, van den Eijkhof F, Hoijtink H, et al. Examining the psychometric characteristics of the Dutch childhood health assessment questionnaire: room for improvement? Rheumatol Int. 2006;26(11):979–83. [PubMed: 16468046]
51. Tennant A, Kearns S, Turner F, et al. Measuring the function of children with juvenile arthritis. Rheumatology (Oxford). 2001;40(11):1274–8. [PubMed: 11709611]
52. van der Net J, Prakken AB, Helders PJ, et al. Correlates of disablement in polyarticular juvenile chronic arthritis--a cross-sectional study. Br J Rheumatol. 1996;35(1):91–100. [PubMed: 8624631]
53. van Kerckhove C, Giannini EH, Lovell DJ. Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. Arthritis Rheum. 1988;31(10):1252–8. [PubMed: 3178907]
54. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41(5):808–16. [PubMed: 9588731]
55. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–57. [PubMed: 10943876]
56. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. [PubMed: 18358927]